Scholar Rock Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Scholar Rock stock.
View analyst ratings for Scholar Rock or view top-rated stocks.

Wall Street analysts have given Scholar Rock a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Scholar Rock wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Scholar Rock is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Scholar Rock.

Scholar Rock Holding Co. (NASDAQ:SRRK) issued its earnings results on Saturday, November, 14th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.26. The business had revenue of $3.04 million for the quarter, compared to the consensus estimate of $6.55 million. Scholar Rock had a negative trailing twelve-month return on equity of 80.16% and a negative net margin of 365.84%.
View Scholar Rock's earnings history.

Scholar Rock's stock was trading at $14.86 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SRRK stock has increased by 259.0% and is now trading at $53.35.
View which stocks have been most impacted by COVID-19.

5 analysts have issued twelve-month price targets for Scholar Rock's stock. Their forecasts range from $39.00 to $79.00. On average, they anticipate Scholar Rock's share price to reach $61.60 in the next twelve months. This suggests a possible upside of 15.5% from the stock's current price.
View analysts' price targets for Scholar Rock or view top-rated stocks among Wall Street analysts.

Some companies that are related to Scholar Rock include Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Kodiak Sciences (KOD), Iovance Biotherapeutics (IOVA), Beam Therapeutics (BEAM), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Relay Therapeutics (RLAY), NanoString Technologies (NSTG), NantKwest (NK), Revolution Medicines (RVMD), Editas Medicine (EDIT) and Sorrento Therapeutics (SRNE).
View all of SRRK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Scholar Rock investors own include Fulcrum Therapeutics (FULC), Coherus BioSciences (CHRS), CTI BioPharma (CTIC), Exelixis (EXEL), GlycoMimetics (GLYC), Nektar Therapeutics (NKTR), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Atara Biotherapeutics (ATRA).

(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."

Scholar Rock's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.88%), BlackRock Inc. (6.28%), Artal Group S.A. (6.24%), Norges Bank (1.87%), Northern Trust Corp (0.92%) and Morgan Stanley (0.74%). Company insiders that own Scholar Rock stock include Gregory John Carven and Michael Gilman.
View institutional ownership trends for Scholar Rock.

SRRK stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Victory Capital Management Inc., JPMorgan Chase & Co., Squarepoint Ops LLC, Nuveen Asset Management LLC, Barclays PLC, Welch & Forbes LLC, and Strs Ohio. Company insiders that have sold Scholar Rock company stock in the last year include Gregory John Carven, and Michael Gilman.
View insider buying and selling activity for Scholar Rock or view top insider-selling stocks.

SRRK stock was acquired by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Norges Bank, BlackRock Inc., Lord Abbett & CO. LLC, Frazier Management LLC, Morgan Stanley, Ikarian Capital LLC, and Federated Hermes Inc..
View insider buying and selling activity for Scholar Rock or or view top insider-buying stocks.

Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SRRK stock can currently be purchased for approximately $53.35.

Scholar Rock has a market capitalization of $1.79 billion and generates $20.49 million in revenue each year. The company earns $-51,000,000.00 in net income (profit) each year or ($1.85) on an earnings per share basis.

Scholar Rock employs 93 workers across the globe.

The official website for Scholar Rock is www.scholarrock.com.

Scholar Rock is headquartered at 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139.

Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]